Wegovy and Ozempic contain the exact same active ingredient, semaglutide, but Wegovy delivers a higher dose and is the only one of the two actually approved for weight loss. In clinical trials, patients taking Wegovy’s top doses lost roughly 15% of their body weight over about 16 months, while patients on Ozempic’s highest dose lost closer to 7% over a shorter period. So yes, Wegovy produces significantly more weight loss, and the reason comes down to dosing, not chemistry.
Same Drug, Different Doses
Both Wegovy and Ozempic are made by Novo Nordisk and both deliver semaglutide, a synthetic version of a gut hormone called GLP-1 that slows digestion, reduces appetite, and signals fullness to the brain. The difference is in how they’re packaged and prescribed. Ozempic is FDA-approved for type 2 diabetes management and tops out at 2.0 mg per week. Wegovy is FDA-approved specifically for chronic weight management and can be prescribed at doses up to 7.2 mg per week, more than three times Ozempic’s ceiling.
This dosing gap is the single biggest reason Wegovy outperforms Ozempic for weight loss. Higher doses of semaglutide suppress appetite more effectively and lead to greater calorie reduction over time. When people use Ozempic off-label for weight loss, they’re getting the same molecule but at a fraction of the dose that was tested and approved for that purpose.
What the Clinical Trials Show
The weight loss data for Wegovy comes from the STEP trial program, a series of large studies that tested semaglutide 2.4 mg (the original top dose) against placebo over 68 weeks. In STEP 1, patients without type 2 diabetes lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. When combined with intensive behavioral therapy and a low-calorie diet in STEP 3, the average loss climbed to 16.0%. Over a full two years in STEP 5, patients maintained a 15.2% reduction in body weight.
People with type 2 diabetes tend to lose less weight on semaglutide. In STEP 2, patients with diabetes averaged a 9.6% body weight reduction at 68 weeks. That’s still substantial, but it reflects the metabolic differences that make weight loss harder when insulin resistance is part of the picture.
Ozempic’s weight loss numbers come from the SUSTAIN trials, which were designed to measure blood sugar control, not weight loss. In SUSTAIN FORTE, patients on Ozempic’s highest available dose of 2.0 mg lost an average of about 6.9 kg (roughly 15 pounds) over 40 weeks. That’s meaningful, but it’s roughly half the percentage of body weight that Wegovy patients lose over a longer treatment period. The comparison isn’t perfectly apples-to-apples since the trials had different designs and patient populations, but the pattern is clear: higher semaglutide doses produce more weight loss.
Side Effects Are Similar but Scale With Dose
Because both drugs use the same molecule, they share the same side effect profile. The most common issues are gastrointestinal: nausea, diarrhea, constipation, vomiting, and abdominal pain. In Wegovy’s clinical trials, 44% of patients reported nausea, 30% experienced diarrhea, 24% had vomiting, 24% had constipation, and 20% reported abdominal pain. Most of these symptoms are worst during the dose escalation phase and tend to improve as the body adjusts.
Both drugs start at the same low dose of 0.25 mg per week and increase gradually over several months to minimize these effects. With Wegovy, though, the escalation continues to much higher doses, which means some people experience a new wave of nausea each time they step up. Less common but more serious risks include gallbladder problems, pancreatic inflammation, and allergic reactions. These apply equally to both medications.
Cardiovascular Benefits Are Proven for Wegovy
Beyond weight loss, Wegovy has a distinct clinical advantage that Ozempic at its lower doses hasn’t been tested for in the same way. The SELECT trial, a landmark study of over 17,000 patients, found that semaglutide 2.4 mg reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with established heart disease and obesity or overweight who did not have diabetes. For patients with heart failure specifically, the risk reduction was even greater, reaching 28% to 35% depending on the type of heart failure.
This is why Wegovy’s FDA approval now includes an indication for reducing cardiovascular risk, in addition to its approval for weight management and, more recently, for a form of fatty liver disease called MASH. Ozempic does not carry these specific approvals.
Insurance Coverage Is a Major Hurdle
Here’s where the practical picture gets complicated. Despite being the better option for weight loss on paper, Wegovy is often harder to get covered by insurance. Most private insurance companies and federal health programs don’t cover weight loss medications. Medicare has been explicitly prohibited by law from covering weight loss treatments since 2003, which blocks coverage for millions of older adults.
This is partly why Ozempic became so popular for off-label weight loss in the first place. Patients with type 2 diabetes can get Ozempic covered as a diabetes medication, and some providers prescribe it to patients who also want weight loss benefits, even though the doses are lower. If you don’t have diabetes, getting either drug covered can be difficult. The out-of-pocket cost for both runs over $1,000 per month without insurance, though prices fluctuate and manufacturer savings programs exist for some patients.
As of early 2025, the FDA has noted that semaglutide no longer appears on the national drug shortage list, which means supply has stabilized after years of intermittent shortages that made both medications hard to find.
Which One Should You Choose?
If your primary goal is weight loss and you can access it, Wegovy is the stronger option. It’s specifically designed for weight management, reaches higher doses, produces nearly twice the percentage of weight loss seen with Ozempic, and has proven cardiovascular benefits at its approved dose. Ozempic is a reasonable alternative if you also have type 2 diabetes and need a single medication that addresses both blood sugar and weight, or if insurance covers Ozempic but not Wegovy.
One thing to keep in mind with either drug: stopping semaglutide typically leads to weight regain. The STEP 4 trial showed that patients who switched from semaglutide to placebo after 20 weeks regained a significant portion of their lost weight, while those who continued treatment maintained their results. This is a long-term, potentially lifelong medication for most people who use it, not a short course you take and stop.